The	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
G	O
protein	O
-	O
coupled	O
receptor	O
as	O
a	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
Kaposi	B-Cancer
'	I-Cancer
s	I-Cancer
sarcoma	I-Cancer
.	O

The	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
(	O
KSHV	O
)	O
encodes	O
a	O
G	O
protein	O
-	O
coupled	O
receptor	O
(	O
vGPCR	O
)	O
that	O
has	O
been	O
implicated	O
in	O
the	O
initiation	O
of	O
Kaposi	B-Cancer
'	I-Cancer
s	I-Cancer
sarcoma	I-Cancer
,	O
identifying	O
vGPCR	O
as	O
an	O
attractive	O
target	O
for	O
preventing	O
Kaposi	B-Cancer
'	I-Cancer
s	I-Cancer
sarcoma	I-Cancer
.	O

However	O
,	O
as	O
only	O
a	O
fraction	O
of	O
cells	B-Cell
in	O
advanced	O
Kaposi	B-Cancer
'	I-Cancer
s	I-Cancer
sarcoma	I-Cancer
lesions	I-Cancer
express	O
vGPCR	O
,	O
it	O
is	O
unclear	O
whether	O
this	O
unique	O
viral	O
oncogene	O
contributes	O
to	O
Kaposi	B-Cancer
'	I-Cancer
s	I-Cancer
sarcoma	I-Cancer
progression	O
.	O

We	O
therefore	O
set	O
out	O
to	O
determine	O
whether	O
the	O
few	O
cells	B-Cell
that	O
express	O
vGPCR	O
in	O
established	O
tumors	B-Cancer
represent	O
an	O
appropriate	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
preexisting	O
Kaposi	B-Cancer
'	I-Cancer
s	I-Cancer
sarcoma	I-Cancer
.	O

To	O
this	O
end	O
,	O
we	O
generated	O
endothelial	B-Cell
cell	I-Cell
lines	I-Cell
stably	O
expressing	O
vGPCR	O
or	O
key	O
KSHV	O
latently	O
expressed	O
proteins	O
(	O
vCyclin	O
,	O
vFlip	O
,	O
and	O
LANA1	O
)	O
.	O

The	O
endothelial	B-Cell
cell	I-Cell
line	I-Cell
expressing	O
vGPCR	O
was	O
rendered	O
sensitive	O
to	O
treatment	O
with	O
the	O
nucleoside	O
analogue	O
ganciclovir	O
by	O
using	O
a	O
bicistronic	O
construct	O
coexpressing	O
the	O
herpes	O
simplex	O
virus	O
1	O
thymidine	O
kinase	O
.	O

S	O
.	O
c	O
.	O
injection	O
into	O
nude	O
mice	O
with	O
mixed	B-Cell
-	I-Cell
cell	I-Cell
populations	I-Cell
formed	O
tumors	B-Cancer
that	O
approximate	O
the	O
ratio	O
of	O
vGPCR	O
-	O
expressing	O
and	O
KSHV	O
latent	O
gene	O
-	O
expressing	O
cells	B-Cell
.	O

These	O
mice	O
were	O
then	O
treated	O
with	O
ganciclovir	O
to	O
specifically	O
target	O
only	O
the	O
vGPCR	O
-	O
expressing	O
cells	B-Cell
.	O

Surprisingly	O
,	O
despite	O
the	O
expression	O
of	O
KSHV	O
latent	O
genes	O
in	O
the	O
vast	O
majority	O
of	O
tumor	B-Cell
cells	I-Cell
,	O
specifically	O
targeting	O
only	O
the	O
few	O
vGPCR	O
-	O
expressing	O
cells	B-Cell
in	O
established	O
tumors	B-Cancer
resulted	O
in	O
tumor	B-Cancer
regression	O
.	O

Moreover	O
,	O
we	O
observed	O
an	O
increase	O
in	O
apoptosis	O
of	O
latent	O
gene	O
-	O
expressing	O
cells	B-Cell
after	O
the	O
pharmacologic	O
deletion	O
of	O
the	O
vGPCR	O
-	O
expressing	O
cells	B-Cell
.	O

These	O
findings	O
indicate	O
that	O
vGPCR	O
may	O
play	O
a	O
key	O
role	O
in	O
Kaposi	B-Cancer
'	I-Cancer
s	I-Cancer
sarcoma	I-Cancer
progression	O
and	O
provide	O
experimental	O
justification	O
for	O
developing	O
molecular	O
-	O
based	O
therapies	O
specifically	O
targeting	O
vGPCR	O
and	O
its	O
effectors	O
for	O
the	O
treatment	O
of	O
Kaposi	B-Cancer
'	I-Cancer
s	I-Cancer
sarcoma	I-Cancer
patients	O
.	O

